XENE ▼ -15.4% - Xenon Pharmaceuticals Inc. $XENE - Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program Xenon Pharmaceuticals fell 15.4% today following news that the company submitted an NDA to the FDA for azetukalner in focal seizures and provided an update on its psychiatry clinical program. While the NDA submission represents a key regulatory milestone, the market's negative reaction suggests investors may have had concerns about the clinical program update or found the psychiatry pipeline advancement insufficient to offset execution risks. 17-SEP-2026 04:01 PM ET